Citation | Ye, XY; Chen, SY; Wu, S; Yoon, DS; Wang, H; Hong, Z; O'Connor, SP; Li, J; Li, JJ; Kennedy, LJ; Walker, SJ; Nayeem, A; Sheriff, S; Camac, DM; Ramamurthy, V; Morin, PE; Zebo, R; Taylor, JR; Morgan, NN; Ponticiello, RP; Harrity, T; Apedo, A; Golla, R; Seethala, R; Wang, M; Harper, TW; Sleczka, BG; He, B; Kirby, M; Leahy, DK; Li, J; Hanson, RL; Guo, Z; Li, YX; DiMarco, JD; Scaringe, R; Maxwell, B; Moulin, F; Barrish, JC; Gordon, DA; Robl, JA Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3'-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11?-Hydroxysteroid Dehydrogenase Type 1 Inhibitor. J Med Chem60:4932-4948 (2017) [PubMed] Article |
---|
SMILES | Fc1ccc(cc1)C1(CC(=O)N2CCCC2)C2CC3CC(C2)CC1C3 |TLB:24:23:21:17.18.19,8:7:17.24.18:22.20.21,4:7:21:17.18.19,THB:24:18:7.23.22:21,19:18:7:22.20.21,19:20:7:17.24.18,8:7:21:17.18.19,4:7:17.24.18:22.20.21,(23.94,-24.95,;23.96,-23.41,;22.63,-22.62,;22.65,-21.09,;23.99,-20.34,;25.31,-21.11,;25.3,-22.64,;24.01,-18.8,;22.86,-17.77,;21.4,-18.25,;20.15,-17.34,;20.92,-19.71,;19.45,-20.18,;19.45,-21.72,;20.91,-22.2,;21.82,-20.95,;25.21,-17.53,;26.53,-18.01,;27.92,-17.67,;27.94,-16.14,;26.54,-15.56,;25.2,-16.04,;25.5,-16.8,;25.5,-18.39,;26.91,-18.95,)| |